Absence or reduction of sexual desire
Conditions
Interventions
Goals:
To observe the effect of the use of transdermal testosterone emulsion on the lipid profile of menacme patients undergoing treatment for hypoactive sexual desire disorder.
- Observe the effect
Sponsors
universidade federal de sao paulo
universidade federal de sao paulo
Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria:Women over 18 years old; maximum age 45 years; Decreased sexual desire; Present sexual activity, with at least one sexual event per month, with current partner; Be in good general health; Women over 40 should have a clinically acceptable mammogram within the last 2 years; Be on contraceptive method.
Exclusion criteria
Exclusion criteria: Exclusion Criteria:Sexual dysfunction caused by another medical condition;Body mass index (BMI) below 18 kg / m2 or above 35 kg / m2; undiagnosed genital bleeding;Use of androgen therapy in the last 6 months (testosterone implant, testosterone transdermal cream, tibolone, oral testosterone or injectable testosterone); Antiandrogenic therapy for acne or hirsutism in the last 5 years; Hyperandrogenism Syndrome, such as Polycystic Ovary Syndrome; Moderate or severe acne, hirsutism, and androgenetic alopecia; Any serious clinical or psychiatric illness, active cancer, or treatment of malignancy within the last six months; Decompensated clinical disease; Any clinically significant skin abnormalities in the study medication application area; Consumption of more than three standard alcoholic drinks per day; pregnancy or lactation; Do not attend our center for follow-up study visits.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome:The primary outcome of the study will be the effect of testosterone at the treatment dose for Hypoactive sexual desire on lipid profile; | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Outcome: As secondary outcomes will be assessed the suffering associated with low desire, which will be measured using FSFI. The change in sexual function as measured by the FSFI, which should be assessed at baseline and week 12. Possible side effects will also be assessed. As well as other laboratory parameters previously mentioned. | — |
Countries
Brazil
Contacts
Public ContactNatasha Meletti
Outcome results
None listed